You seemed misinformed.
The only sales force at Abbvie which is heavy on reps, is our primary care sales force. Those folks have known for a while to be on the “lookout” for new jobs. With that being said, Abbvie has a history of taking care of its people, and placing them in new jobs, specifically when faced with downsizing a specific sales force. Also, Abbvie’s history shows it does not get rid of representatives from companies they have acquired, as evidenced by our Solvay sales force.
As for the rest of Abbvie’s sales force. We work under a “lean” model. We have less than 400 total Humira representatives, which generate about 7 billion dollars in business a year.
According to this post, Shire has a little over 500 representatives in the entire company, which generate slightly over 500 million dollars a year, across all Shire products.
So stop speculating. It doesn’t seem likely either Abbvie or Shire’s sales forces will be downsized, due to the merger.
Man everything you have stated above is essentially
the complete opposite of what history with Abbvie/abbott
has shown to be true. You need a history lesson
and a Koolaid antedote. Keep telling yourself
that all is going to be fine, the sales force
redundancies are not obvious, and you will be
well treated. Get a clue. It's clearly a mental
and reasoning deficit that you are sadly living with.
If you are personal buds with Little Ricky, you might be safe. Otherwise beware. These huge deals ALWAYS result in massive cuts. You think Humira needs 4 reps per territory calling on a total of 15 viable writers? You don't think docs find this constant nagging to be annoying? You don't think that every pharma employee including the janitors know that this shit has to be curtailed? This kind of major merger tide change will bring all that ridiculous overlap to the forefront. You think specialty is truly special in the eyes of a mega billion dollar conglomerate with the major access and healthcare challenges in the USA?
Its all about cost cost and cost amongst similar treatments in a particular disease state. There is no "primary care" per se at AbbVie anymore. Every franchise has a make believe specialty title.
Wake the hell up man. If you are counting on these pretend sales jobs for the long haul, you are out of luck.
Metabolic is a perfect example. Me, I'm getting the hell out of Dodge and taking my locked in retirement benefit while it still exists.
You seemed misinformed.
The only sales force at Abbvie which is heavy on reps, is our primary care sales force. Those folks have known for a while to be on the “lookout” for new jobs. With that being said, Abbvie has a history of taking care of its people, and placing them in new jobs, specifically when faced with downsizing a specific sales force. Also, Abbvie’s history shows it does not get rid of representatives from companies they have acquired, as evidenced by our Solvay sales force.
As for the rest of Abbvie’s sales force. We work under a “lean” model. We have less than 400 total Humira representatives, which generate about 7 billion dollars in business a year.
According to this post, Shire has a little over 500 representatives in the entire company, which generate slightly over 500 million dollars a year, across all Shire products.
So stop speculating. It doesn’t seem likely either Abbvie or Shire’s sales forces will be downsized, due to the merger.
Vyvanse does 1.5 billion per year with about 400 reps
I'm so happy about this deal. Besides the tax benefits, the pipeline of products will be the real key. This pipeline ensures us growth for the next 10 years. Since I plan on retiring in 2025 this is perfect. Thanks Rickey boy, yo finally did a good job.
I'm good dude....not even a little worried about job security. I've been in this industry for over 20 years and have never been laid off.
Become invaluable
Shire is a mid sized specialty pharma company with decent upside. Here is the breakdown on their divisions:
Behavioral Health/ Neuro-Psych - 350 Reps
This divisions drives most of Shire's revenue. Vyvanse does not go generic till 2023.
- Vyvanse (adult/ ped ADHD)
- Adderall xr 3 (adult ADHD)
GI -100 Reps
Smaller division that has been cut back over the years
- Lialda (Ulcerative colitis)
Rare Disease - 60 Reps
Shire purchased ViroPharma last year and currently promotes 4 drugs in this category. They also have a few things in the pipeline. This is also a pretty profitable segment of Shire.
Ophthalmology - 0 reps
This division is in the pipeline with a couple of drugs coming to maket in the next year. They will be launching a new med for chronic dry eyes and will also promote a drug for a rare condition involving pediatriac blindness.
Man, you guys are so immature. Pretty sad if this represents who just bought us. Take a look at the track record of our (Shire)sales force. It's one of the reasons we got bought and sold for $54 billion. You guys may be surprised to see who gets cut first. My money is on the Shire reps (CNS) keeping their jobs. Why would you mess with success?
Now what?
Vyvanse does 1.5 billion per year with about 400 reps
And would do the same with no reps.
